395 results about "Sleeping disorders" patented technology

The present invention provides systems and methods for selectively applying electrical energy to a target location within the head and neck of a patient's body, particularly including tissue in the ear, nose and throat. The present invention applies high frequency (RF) electrical energy to one or more electrode terminals in the presence of electrically conductive fluid to remove and/or modify the structure of tissue structures. The present invention is particularly useful for treating sleep obstructive disorders, such as sleep apnea and snoring.

An electronic system and method for detecting analytes, such as carbon dioxide, is provided, using an improved nanostructure sensor (CO2 sensor). The CO2 sensor may comprise a substrate and a nanostructure, such as a one or more carbon nanotubes disposed over the substrate (e.g., as a network). One or more conductive elements may electrically communicate with the nanostructure. A counter or gate electrode may be positioned adjacent the nanostructure. A functionalization material reactive with carbon dioxide may be included, either disposed in contact with the nanostructure or isolated by a dielectric. The sensor may be connected to a circuit responsive to changes in CO2 concentration in the environment. Embodiments are described of medical sensing systems including one or more CO2 sensors. One embodiment comprises a breath sampling cannula which is connected to a sensor unit. In an alternative, the cannula permits supplemental oxygen to be administered, while recovering and measuring analytes in breath samples. The cannula may connect to a portable processor-display unit for monitoring one or more analytes, such as CO2. Another embodiment includes a cannula configured for the monitoring of sleep disorders, such as apnea, comprising one or more sensors disposed adjacent a breath sampling channel, optionally including flow rate or other sensors. The sensors may be connected by wired or wireless links for to a processor/input/display unit. Any of the embodiments may include filters, selectively permeable membranes, absorbents, and the like to precondition the breath sample, may be configured to include complementary chemistry measurements.

Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder in a subject, methods for ameliorating a symptom of schizophrenia, schizoaffective disorder, or other psychotic disorder in a subject, methods for ameliorating a symptom of a depressive disorder in a subject, methods for ameliorating a symptom of bipolar disorder in a subject, methods for ameliorating a symptom of post-traumatic stress disorder or other anxiety disorder in a subject, methods for predicting a predisposition to suicide, suicidal ideation, suicidal behavior, or a combination thereof in a subject, methods for ameliorating a symptom of a pain disorder in a subject, methods for ameliorating a neurodegenerative disorder in a subject, methods for ameliorating a symptom of traumatic brain injury in a subject, methods for ameliorating a sleep disorder in a subject, and methods for improving cognitive functioning in a subject. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition comprising pregnenolone (PG), allopregnanolone (ALLO), dehydroepiandrosterone (DHEA), progesterone (PROG), precursors thereof, metabolites thereof, pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof.

The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I)

or pharmaceutically acceptable salt forms thereof, wherein R¹, R⁵, R^6a, R^6b, R⁷, R⁸, R⁹, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

The invention discloses a sleepy obstacle measuring device and method of limitless and non-awareness, which is characterized by the following: setting the pickup and microprocessor in the pillow; placing the microphone on two sides of pillow toward the detector mouth and nose to receive the sound in the phonetic interface of microprocessor; transmitting the magnified sound signal through microphone to the microprocessor; proceeding sound signal filter and intelligent judgment of limitless and non-awareness sleepy obstacle measurement; judging the sleep respiratory and sleep respiratory hesitation symptom; sending the judgment result to the specialist through interface to treat and improve the sleepy obstacle.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I) and (III): where R¹, R², R³, R^3′, R₄, R^6a, R^6a, R^11a, and R^11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.

This invention provides methods of administering (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclo-propyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder.

A method for moderating sleep disorder of a patient includes non-invasively and concurrently electric and magnetic stimulating a group of stimulation areas in a head minimally including vital point baihui DU20 and its vicinity or surrounding area. The electric and magnetic simulation form a mesh like stimulation pattern in the head and has the steps of serially connecting DU20, DU21, DU19 and two GB18 areas for a first polarity electrical stimulation and serially connecting of DU24, two UB4, two SJ20 and two GB6 areas for a second polarity electrical stimulation and has the step of incorporating the same polarity 1 of a permanent magnet placed facing down on DU24, two GB6, DU21, DU19, two GB18, two GB6 and two UB7 areas and the same but opposite to polarity 1 of a permanent magnet placed facing down on two UB4, two SJ20, DU22, DU20 and DU18 areas.

The present invention provides a method for managing a patient having a sleep disorder, e.g. sleep apnea, snoring, sleep bruxism, upper airway resistance syndrome, etc. The method comprises monitoring physiological information from the patient, converting the physiological information to digital data, storing the digital data in a digital memory, identifying and characterizing epochs based on the digital data, and storing the identifying and characterizing information of the epochs in a digital memory. The method further comprises organizing the epochs according to an organization function that considers at least characterization information of the epochs, selecting an epoch based on the organizing of the epochs, and generating sound derived from the stored digital data associated with the selected epoch such that the patient hears the sound. In a specific embodiment, the physiological information monitored may include sound, e.g. respiratory sound emanating from the trachea, and/or tooth-grinding sounds.

This invention relates to a method for treating and preventing neurological disorders related to rapid-eye-movement (REM) sleep disturbances in a mammal comprising administering to the mammal an amount of an NPY Y5 receptor antagonist which effectively reduces REM sleep.

Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.

The invention is directed to compositions used for treating sleep disorders. In addition, the invention provides convenient methods of treatment of a sleep disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of ester derivatized trazodone compounds for the treatment of sleep disorders.

The present invention discloses and claims compounds of formula (I)

as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.

The present disclosure relates to a method for treating sleep disorders using an intra-oral appliance and to the fabrication of an intra-oral appliance that incorporates digital information into the process so as to increase efficiency and decrease cost. The method includes a data capture step and a fabrication step.

The present invention provides a circadian rhythm normalizing composition containing astaxanthin and/or its ester as an active ingredient, and a composition having the action of enhancing the circadian rhythm normalizing action of melatonin by protecting melatonin. The composition can be in the form of a drug, a functional food, a food or a beverage.

This composition has a circadian rhythm normalizing action, and has the action of preventing or alleviating sleep disorder and various diseases due to disturbance of the circadian rhythm.

The present invention is directed to methods for identification of compounds that affect wakefulness, attention deficit hyperactivity disorder, chronic fatigue syndrome and mood disorders (e.g., depression) through interaction with the hypocretin receptor system. The present invention is also directed to detection of abnormal levels of hypocretin in a subject, as well as detection of an abnormal immune response against hypocretin (orexins) and/or their receptors, where detection of abnormal hypocretin levels or detection of an abnormal immune response is indicative of a sleep disorder, particularly of narcolepsy. The present invention is also directed to a methods relating to the detection of a mutation or polymorphism in the gene encoding the hypocretin receptors, the detection of antibodies disrupting the function of gene encoding hypocretin receptors and hypocretin polypeptides, and the use of hypocretin biological markers in predicting treatment response using compounds interacting with the hypocretin receptor system.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus.